Natixis Advisors
CPRX

Natixis Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

Natixis Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$571K Buy
18,186
+3,745
+26% +$111K ﹤0.01% 1658
2026
Q1 		$358K Buy
14,441
+1,410
+11% +$33.6K ﹤0.01% 1616
2025
Q4 		$304K Sell
13,031
-44,716
-77% -$996K ﹤0.01% 1546
2025
Q3 		$1.14M Sell
57,747
-14,396
-20% -$296K ﹤0.01% 1273
2025
Q2 		$1.57M Buy
72,143
+9,153
+15% +$216K ﹤0.01% 1164
2025
Q1 		$1.53M Buy
62,990
+3,737
+6% +$84.2K ﹤0.01% 1161
2024
Q4 		$1.24M Buy
59,253
+13,616
+30% +$293K ﹤0.01% 1243
2024
Q3 		$907K Buy
45,637
+12,491
+38% +$232K ﹤0.01% 1323
2024
Q2 		$513K Buy
+33,146
New +$516K ﹤0.01% 1429
2024
Q1 		– Sell
-12,097
Closed -$203K – 1536
2023
Q4 		$203K Buy
+12,097
New +$165K ﹤0.01% 1516
2023
Q1 		– Sell
-15,367
Closed -$286K – 1470
2022
Q4 		$286K Buy
+15,367
New +$237K ﹤0.01% 1403

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Natixis Advisors's CPRX Position: Q2 2026 in Review

Natixis Advisors increased its Catalyst Pharmaceutical (CPRX) stake by 26% in Q2 2026, buying an estimated $111K and bringing the position to 18,186 shares worth $571K. The position accounts for ﹤0.01% of the portfolio, ranked #1658.

Natixis Advisors first reported a position in CPRX in Q4 2022 and has held it in 11 quarters since. The position peaked at $1.57M in Q2 2025. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • Natixis Advisors held 18,186 shares of Catalyst Pharmaceutical worth $571K as of Q2 2026.
  • Natixis Advisors bought 3,745 Catalyst Pharmaceutical shares in Q2 2026, an estimated $111K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Natixis Advisors's portfolio in Q2 2026, its #1658 holding.
  • Natixis Advisors first reported a position in Catalyst Pharmaceutical in Q4 2022 and has held it in 11 quarters since.
  • Natixis Advisors's Catalyst Pharmaceutical position peaked at $1.57M in Q2 2025.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.